title: [Recent treatment for medication-related osteonecrosis of the jaw].
abstract: The mechanism and etiopathogenesis of medication-related osteonecrosis of the jaw (MRONJ) have never been unclear. Therefore, there is no consensus regarding the clinical management of patients with MRONJ. In Japan, Bisphosphonate-Related Osteonecrosis of the Jaw:Position Paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial, Radiology and Japanese Society of Oral and Maxillofacial Surgeons is frequently used as criterion. The purpose of this paper is discussing about MRONJ according to the Japanese position paper.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Tokai University, School of Medicine, Japan.
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Ota
authors.affiliation: Department of Oral and Maxillofacial Surgery, Tokai University, School of Medicine, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Sasaki
mesh_terms: D015415:Biomarkers / Q000032:analysis; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000188:drug therapy* / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000737:chemistry / Q000378:metabolism; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates